1. Picciotto, M. R., Higley, M. J. & Mineur, Y. S. (2012) Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior, Neuron. 76, 116-29.
2. Klinkenberg, I. & Blokland, A. (2010) The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies, Neurosci Biobehav Rev. 34, 1307-50.
3. Shiozaki, K., Iseki, E., Uchiyama, H., Watanabe, Y., Haga, T., Kameyama, K., Ikeda, T., Yamamoto, T. & Kosaka, K. (1999) Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: relation to Alzheimer's disease, J Neurol Neurosurg Psychiatry. 67, 209-13.
4. Tiraboschi, P., Hansen, L. A., Alford, M., Sabbagh, M. N., Schoos, B., Masliah, E., Thal, L. J. & Corey-Bloom, J. (2000) Cholinergic dysfunction in diseases with Lewy bodies, Neurology. 54, 407-11.
5. Ballard, C., Piggott, M., Johnson, M., Cairns, N., Perry, R., McKeith, I., Jaros, E., O'Brien, J., Holmes, C. & Perry, E. (2000) Delusions associated with elevated muscarinic binding in dementia with Lewy bodies, Ann Neurol. 48, 868-76.
6. Bartus, R. T., Dean, R. L., 3rd, Beer, B. & Lippa, A. S. (1982) The cholinergic hypothesis of geriatric memory dysfunction, Science. 217, 408-14.
7. Hall, H., Reyes, S., Landeck, N., Bye, C., Leanza, G., Double, K., Thompson, L., Halliday, G. & Kirik, D. (2014) Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease, Brain. 137, 2493-508.
8. Samuel, W., Alford, M., Hofstetter, C. R. & Hansen, L. (1997) Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density, J Neuropathol Exp Neurol. 56, 499-508.
9. Tiraboschi, P., Hansen, L. A., Alford, M., Merdes, A., Masliah, E., Thal, L. J. & Corey-Bloom, J. (2002) Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease, Arch Gen Psychiatry. 59, 946-51.
10. Bierer, L. M., Haroutunian, V., Gabriel, S., Knott, P. J., Carlin, L. S., Purohit, D. P., Perl, D. P., Schmeidler, J., Kanof, P. & Davis, K. L. (1995) Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits, J Neurochem. 64, 749-60.
11. Rolinski, M., Fox, C., Maidment, I. & McShane, R. (2012) Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease, Cochrane Database Syst Rev, CD006504.
12. Birks, J. (2006) Cholinesterase inhibitors for Alzheimer's disease, Cochrane Database Syst Rev, CD005593.
13. Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., Hurley, D. J., Potter, W. Z. & Paul, S. M. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease, Arch Neurol. 54, 465-73.
14. Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dube, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L. & Felder, C. C. (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia, Am J Psychiatry. 165, 1033-9.
15. Levey, A. I. (1993) Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain, Life Sci. 52, 441-8.
16. Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M. & Silva, A. J. (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice, Nat Neurosci. 6, 51-8.
17. Gould, R. W., Dencker, D., Grannan, M., Bubser, M., Zhan, X., Wess, J., Xiang, Z., Locuson, C., Lindsley, C. W., Conn, P. J. & Jones, C. K. (2015) Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice, ACS Chem Neurosci. 6, 1683-95.
18. Conn, P. J., Christopoulos, A. & Lindsley, C. W. (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders, Nat Rev Drug Discov. 8, 41-54.
19. Jones, C. K., Byun, N. & Bubser, M. (2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia, Neuropsychopharmacology. 37, 16-42.
20. Inglis, F. (2002) The tolerability and safety of cholinesterase inhibitors in the treatment of dementia, Int J Clin Pract Suppl, 45-63.
21. Stinton, C., McKeith, I., Taylor, J. P., Lafortune, L., Mioshi, E., Mak, E., Cambridge, V., Mason, J., Thomas, A. & O'Brien, J. T. (2015) Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis, Am J Psychiatry. 172, 731-42.
22. Hansen, R. A., Gartlehner, G., Webb, A. P., Morgan, L. C., Moore, C. G. & Jonas, D. E. (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis, Clin Interv Aging. 3, 211-25.
23. Ito, Y., Oyunzul, L., Seki, M., Fujino Oki, T., Matsui, M. & Yamada, S. (2009) Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice, Br J Pharmacol. 156, 1147-53.
24. Kurimoto, E., Matsuda, S., Shimizu, Y., Sako, Y., Mandai, T., Sugimoto, T., Sakamoto, H. & Kimura, H. (2018) An Approach to Discovering Novel Muscarinic M1 Receptor Positive Allosteric Modulators with Potent Cognitive Improvement and Minimized Gastrointestinal Dysfunction, J Pharmacol Exp Ther. 364, 28-37.
25. Alt, A., Pendri, A., Bertekap, R. L., Jr., Li, G., Benitex, Y., Nophsker, M., Rockwell, K. L., Burford, N. T., Sum, C. S., Chen, J., Herbst, J. J., Ferrante, M., Hendricson, A., Cvijic, M. E., Westphal, R. S., O'Connell, J., Banks, M., Zhang, L., Gentles, R. G., Jenkins, S., Loy, J. & Macor, J. E. (2016) Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors, J Pharmacol Exp Ther. 356, 293- 304.
26. Davoren, J. E., Lee, C. W., Garnsey, M., Brodney, M. A., Cordes, J., Dlugolenski, K., Edgerton, J. R., Harris, A. R., Helal, C. J., Jenkinson, S., Kauffman, G. W., Kenakin, T. P., Lazzaro, J. T., Lotarski, S. M., Mao, Y., Nason, D. M., Northcott, C., Nottebaum, L., O'Neil, S. V., Pettersen, B., Popiolek, M., Reinhart, V., Salomon-Ferrer, R., Steyn, S. J., Webb, D., Zhang, L. & Grimwood, S. (2016) Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3- thiazol-4-yl)ben zyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects, J Med Chem. 59, 6313-28.
27. Rasmusson, D. D. (2000) The role of acetylcholine in cortical synaptic plasticity, Behav Brain Res. 115, 205-18.
28. Blokland, A. (1995) Acetylcholine: a neurotransmitter for learning and memory?, Brain Res Rev. 21, 285-300.
29. Lange, H. S., Cannon, C. E., Drott, J. T., Kuduk, S. D. & Uslaner, J. M. (2015) The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys, J Pharmacol Exp Ther. 355, 442-50.
30. Uslaner, J. M., Eddins, D., Puri, V., Cannon, C. E., Sutcliffe, J., Chew, C. S., Pearson, M., Vivian, J. A., Chang, R. K., Ray, W. J., Kuduk, S. D. & Wittmann, M. (2013) The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque, Psychopharmacology (Berl). 225, 21-30.
31. Puri, V., Wang, X., Vardigan, J. D., Kuduk, S. D. & Uslaner, J. M. (2015) The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model, Behav Brain Res. 287, 96-9.
32. Bradley, S. J., Bourgognon, J. M., Sanger, H. E., Verity, N., Mogg, A. J., White, D. J., Butcher, A. J., Moreno, J. A., Molloy, C., Macedo-Hatch, T., Edwards, J. M., Wess, J., Pawlak, R., Read, D. J., Sexton, P. M., Broad, L. M., Steinert, J. R., Mallucci, G. R., Christopoulos, A., Felder, C. C. & Tobin, A. B. (2017) M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss, J Clin Invest. 127, 487-499.
33. Sako, Y., Kurimoto, E., Mandai, T., Suzuki, A., Tanaka, M., Suzuki, M., Shimizu, Y., Yamada, M. & Kimura, H. (2019) TAK-071, a Novel M1 Positive Allosteric Modulator with Low Cooperativity, Improves Cognitive Function in Rodents with Few Cholinergic Side Effects, Neuropsychopharmacology. 44, 950-960.
34. Uslaner, J. M., Kuduk, S. D., Wittmann, M., Lange, H. S., Fox, S. V., Min, C., Pajkovic, N., Harris, D., Cilissen, C., Mahon, C., Mostoller, K., Warrington, S. & Beshore, D. C. (2018) Preclinical to Human Translational Pharmacology of the Novel M1 Positive Allosteric Modulator MK-7622, J Pharmacol Exp Ther. 365, 556-566.
35. Beshore, D. C., C, N. D. M., Chang, R. K., Greshock, T. J., Ma, L., Wittmann, M., Seager, M. A., Koeplinger, K. A., Thompson, C. D., Fuerst, J., Hartman, G. D., Bilodeau, M. T., Ray, W. J. & Kuduk, S. D. (2018) MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate, ACS Med Chem Lett. 9, 652-656.
36. Voss, T., Li, J., Cummings, J., Farlow, M., Assaid, C., Froman, S., Leibensperger, H., Snow-Adami, L., McMahon, K. B., Egan, M. & Michelson, D. (2018) Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease, Alzheimers Dement. 4, 173-181.
37. Lim, Y., Kehm, V. M., Li, C., Trojanowski, J. Q. & Lee, V. M. (2010) Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption, Exp Neurol. 221, 86-97.
38. Lim, Y., Kehm, V. M., Lee, E. B., Soper, J. H., Li, C., Trojanowski, J. Q. & Lee, V. M. (2011) alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies, J Neurosci. 31, 10076-87.
39. Mayford, M., Bach, M. E., Huang, Y. Y., Wang, L., Hawkins, R. D. & Kandel, E. R. (1996) Control of memory formation through regulated expression of a CaMKII transgene, Science. 274, 1678-83.
40. Sugimoto, T., Suzuki, S., Sakamoto, H., Yamada, M., Nakamura, M., Kamata, M., Shimokawa, K., Ogino, M., Kimura, E., Murakami, M., Yonemori, J. & Kojima, T. 2,3- dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor, patent WO2016208775. 2016 Dec 29.
41. Lazareno, S. & Birdsall, N. J. (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors, Mol Pharmacol. 48, 362-78.
42. Hughes, R. N. (2004) The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory, Neurosci Biobehav Rev. 28, 497-505.
43. Racine, R. J. (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure, Electroencephalogr Clin Neurophysiol. 32, 281-94.
44. Atack, J. R., Cook, S. M., Watt, A. P. & Ragan, C. I. (1992) Measurement of lithium- induced changes in mouse inositol(1)phosphate levels in vivo, J Neurochem. 59, 1946- 54.
45. Trinquet, E., Fink, M., Bazin, H., Grillet, F., Maurin, F., Bourrier, E., Ansanay, H., Leroy, C., Michaud, A., Durroux, T., Maurel, D., Malhaire, F., Goudet, C., Pin, J. P., Naval, M., Hernout, O., Chretien, F., Chapleur, Y. & Mathis, G. (2006) D-myo-inositol 1- phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein- coupled receptor activation, Anal Biochem. 358, 126-35.
46. van Koppen, C. J. & Kaiser, B. (2003) Regulation of muscarinic acetylcholine receptor signaling, Pharmacol Ther. 98, 197-220.
47. Davis, A. A., Heilman, C. J., Brady, A. E., Miller, N. R., Fuerstenau-Sharp, M., Hanson, B. J., Lindsley, C. W., Conn, P. J., Lah, J. J. & Levey, A. I. (2010) Differential effects of allosteric M(1) muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation, ACS Chem Neurosci. 1, 542-551.
48. Thomas, R. L., Langmead, C. J., Wood, M. D. & Challiss, R. A. (2009) Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation, J Pharmacol Exp Ther. 331, 1086-95.
49. Vardigan, J. D., Cannon, C. E., Puri, V., Dancho, M., Koser, A., Wittmann, M., Kuduk, S. D., Renger, J. J. & Uslaner, J. M. (2015) Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey, Psychopharmacology (Berl). 232, 1859-66.
50. Whitfield, D. R., Vallortigara, J., Alghamdi, A., Howlett, D., Hortobagyi, T., Johnson, M., Attems, J., Newhouse, S., Ballard, C., Thomas, A. J., O'Brien, J. T., Aarsland, D. & Francis, P. T. (2014) Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment, Neurobiol Aging. 35, 2836-2844.
51. Kramer, M. L. & Schulz-Schaeffer, W. J. (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies, J Neurosci. 27, 1405-10.
52. Bereczki, E., Francis, P. T., Howlett, D., Pereira, J. B., Hoglund, K., Bogstedt, A., Cedazo-Minguez, A., Baek, J. H., Hortobagyi, T., Attems, J., Ballard, C. & Aarsland, D. (2016) Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia, Alzheimers Dement. 12, 1149-1158.
53. Calderon, J., Perry, R. J., Erzinclioglu, S. W., Berrios, G. E., Dening, T. R. & Hodges, J. R. (2001) Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease, J Neurol Neurosurg Psychiatry. 70, 157-64.
54. Sahgal, A., Galloway, P. H., McKeith, I. G., Lloyd, S., Cook, J. H., Ferrier, I. N. & Edwardson, J. A. (1992) Matching-to-sample deficits in patients with senile dementias of the Alzheimer and Lewy body types, Arch Neurol. 49, 1043-6.
55. Pagonabarraga, J., Kulisevsky, J., Llebaria, G., Garcia-Sanchez, C., Pascual-Sedano, B. & Gironell, A. (2008) Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease, Mov Disord. 23, 998-1005.
56. Mori, E., Ikeda, M. & Kosaka, K. (2012) Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial, Ann Neurol. 72, 41-52.
57. Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A. J., Schumann, G., Pourcher, E., Gray, J., Thomas, G., Swartz, J., Hsu, T. & Moline, M. L. (2012) Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study, Mov Disord. 27, 1230-8.
58. Murakami, K., Watanabe, T., Koike, T., Kamata, M., Igari, T. & Kondo, S. (2016) Pharmacological properties of a novel and potent gamma-secretase modulator as a therapeutic option for the treatment of Alzheimer's disease, Brain Res. 1633, 73-86.
59. Nagakura, A., Shitaka, Y., Yarimizu, J. & Matsuoka, N. (2013) Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine, Eur J Pharmacol. 703, 53-61.
60. Davie, B. J., Christopoulos, A. & Scammells, P. J. (2013) Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits, ACS Chem Neurosci. 4, 1026-48.
61. Teles-Grilo Ruivo, L. M., Baker, K. L., Conway, M. W., Kinsley, P. J., Gilmour, G., Phillips, K. G., Isaac, J. T. R., Lowry, J. P. & Mellor, J. R. (2017) Coordinated Acetylcholine Release in Prefrontal Cortex and Hippocampus Is Associated with Arousal and Reward on Distinct Timescales, Cell Rep. 18, 905-917.
62. Howe, W. M., Gritton, H. J., Lusk, N. A., Roberts, E. A., Hetrick, V. L., Berke, J. D. & Sarter, M. (2017) Acetylcholine Release in Prefrontal Cortex Promotes Gamma Oscillations and Theta-Gamma Coupling during Cue Detection, J Neurosci. 37, 3215- 3230.
63. Moran, S. P., Dickerson, J. W., Cho, H. P., Xiang, Z., Maksymetz, J., Remke, D. H., Lv, X., Doyle, C. A., Rajan, D. H., Niswender, C. M., Engers, D. W., Lindsley, C. W., Rook, J. M. & Conn, P. J. (2018) M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition, Neuropsychopharmacology. 43, 1763-1771.
64. Bradley, S. J., Molloy, C., Bundgaard, C., Mogg, A. J., Thompson, K. J., Dwomoh, L., Sanger, H. E., Crabtree, M. D., Brooke, S. M., Sexton, P. M., Felder, C. C., Christopoulos, A., Broad, L. M., Tobin, A. B. & Langmead, C. J. (2018) Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes, Mol Pharmacol. 93, 645-656.
65. Moran, S. P., Cho, H. P., Maksymetz, J., Remke, D. H., Hanson, R. M., Niswender, C. M., Lindsley, C. W., Rook, J. M. & Conn, P. J. (2018) PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems, ACS Chem Neurosci. 9, 2218-2224.
66. Chesselet, M. F. & Richter, F. (2011) Modelling of Parkinson's disease in mice, Lancet Neurol. 10, 1108-18.
67. Fibiger, H. C. (1991) Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence, Trends Neurosci. 14, 220-3.
68. Whitehouse, P. J., Price, D. L., Struble, R. G., Clark, A. W., Coyle, J. T. & Delon, M. R. (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain, Science. 215, 1237-9.
69. McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., Lennox, G., Quinn, N. P., Edwardson, J. A., Ince, P. G., Bergeron, C., Burns, A., Miller, B. L., Lovestone, S., Collerton, D., Jansen, E. N., Ballard, C., de Vos, R. A., Wilcock, G. K., Jellinger, K. A. & Perry, R. H. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop, Neurology. 47, 1113-24.
70. Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L. & Dean, B. (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation, Biol Psychiatry. 48, 381-8.
71. Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L. & Dean, B. (2001) Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment, Am J Psychiatry. 158, 918-25.
72. el-Mallakh, R. S., Kirch, D. G., Shelton, R., Fan, K. J., Pezeshkpour, G., Kanhouwa, S., Wyatt, R. J. & Kleinman, J. E. (1991) The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia, J Neuropsychiatry Clin Neurosci. 3, 383-6.
73. Domino, E. F., Krause, R. R. & Bowers, J. (1973) Various enzymes involved with putative neurotransmitters. Regional distribution in the brain of deceased mentally normal, chronic schizophrenics or organic brain syndrome patients, Arch Gen Psychiatry. 29, 195- 201.
74. Haroutunian, V., Davidson, M., Kanof, P. D., Perl, D. P., Powchik, P., Losonczy, M., McCrystal, J., Purohit, D. P., Bierer, L. M. & Davis, K. L. (1994) Cortical cholinergic markers in schizophrenia, Schizophr Res. 12, 137-44.
75. Thal, L. J., Forrest, M., Loft, H. & Mengel, H. (2000) Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group, Neurology. 54, 421-6.
76. Wienrich, M., Ceci, A., Ensinger, H. A., Gaida, W., Mendla, K. D., Osugi, T., Raschig, A. & Weiser, T. (2002) Talsaclidine (WAL 2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease, Drug Dev Res. 56, 321-334.
77. Heidrich, A. & Rösler, M. (1999) Milameline: Nonselective, Partial Muscarinic Receptor Agonist for the Treatment of Alzheimer's Disease?, Drug Dev Res. 5, 93-104.
78. Bymaster, F. P., Whitesitt, C. A., Shannon, H. E., DeLapp, N., Ward, J. S., Calligaro, D. O., Shipley, L. A., Buelke-Sam, J. L., Bodick, N. C., Farde, L., Sheardown, M. J., Olesen, P. H., Hansen, K. T., Suzdak, P. D., Swedberg, M. D., Sauerberg, P. & Mitch, C. H. (1997) Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease, Drug Dev Res. 40, 158-170.
79. Watson, J., Brough, S., Coldwell, M. C., Gager, T., Ho, M., Hunter, A. J., Jerman, J., Middlemiss, D. N., Riley, G. J. & Brown, A. M. (1998) Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors, Br J Pharmacol. 125, 1413-20.
80. Woolley, M. L., Carter, H. J., Gartlon, J. E., Watson, J. M. & Dawson, L. A. (2009) Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice, Eur J Pharmacol. 603, 147-9.
81. Ghoshal, A., Rook, J. M., Dickerson, J. W., Roop, G. N., Morrison, R. D., Jalan- Sakrikar, N., Lamsal, A., Noetzel, M. J., Poslusney, M. S., Wood, M. R., Melancon, B. J., Stauffer, S. R., Xiang, Z., Daniels, J. S., Niswender, C. M., Jones, C. K., Lindsley, C. W. & Conn, P. J. (2016) Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model, Neuropsychopharmacology. 41, 598-610.
82. Xiu, J., Zhang, Q., Zhou, T., Zhou, T. T., Chen, Y. & Hu, H. (2014) Visualizing an emotional valence map in the limbic forebrain by TAI-FISH, Nat Neurosci. 17, 1552-9.
83. Clayton, D. F. (2000) The genomic action potential, Neurobiol Learn Mem. 74, 185- 216.
84. Lein, E. S.Hawrylycz, M. J.Ao, N.Ayres, M.Bensinger, A.Bernard, A.Boe, A. F.Boguski, M. S.Brockway, K. S.Byrnes, E. J.Chen, L.Chen, T. M.Chin, M. C.Chong, J.Crook, B. E.Czaplinska, A.Dang, C. N.Datta, S.Dee, N. R.Desaki, A. L.Desta, T.Diep, E.Dolbeare, T. A.Donelan, M. J.Dong, H. W.Dougherty, J. G.Duncan, B. J.Ebbert, A. J.Eichele, G.Estin, L. K.Faber, C.Facer, B. A.Fields, R.Fischer, S. R.Fliss, T. P.Frensley, C.Gates, S. N.Glattfelder, K. J.Halverson, K. R.Hart, M. R.Hohmann, J. G.Howell, M. P.Jeung, D. P.Johnson, R. A.Karr, P. T.Kawal, R.Kidney, J. M.Knapik, R. H.Kuan, C. L.Lake, J. H.Laramee, A. R.Larsen, K. D.Lau, C.Lemon, T. A.Liang, A. J.Liu, Y.Luong, L. T.Michaels, J.Morgan, J. J.Morgan, R. J.Mortrud, M. T.Mosqueda, N. F.Ng, L. L.Ng, R.Orta, G. J.Overly, C. C.Pak, T. H.Parry, S. E.Pathak, S. D.Pearson, O. C.Puchalski, R. B.Riley, Z. L.Rockett, H. R.Rowland, S. A.Royall, J. J.Ruiz, M. J.Sarno, N. R.Schaffnit, K.Shapovalova, N. V.Sivisay, T.Slaughterbeck, C. R.Smith, S. C.Smith, K. A.Smith, B. I.Sodt, A. J.Stewart, N. N.Stumpf, K. R.Sunkin, S. M.Sutram, M.Tam, A.Teemer, C. D.Thaller, C.Thompson, C. L.Varnam, L. R.Visel, A.Whitlock, R. M.Wohnoutka, P. E.Wolkey, C. K.Wong, V. Y.Wood, M., et al. (2007) Genome-wide atlas of gene expression in the adult mouse brain, Nature. 445, 168-76.
85. Jones, C. A., Watson, D. J. & Fone, K. C. (2011) Animal models of schizophrenia, Br J Pharmacol. 164, 1162-94.
86. Trinquet, E., Bouhelal, R. & Dietz, M. (2011) Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-One assay, Expert Opin Drug Discov. 6, 981-94.
87. Bartolomeo, A. C., Morris, H., Buccafusco, J. J., Kille, N., Rosenzweig-Lipson, S., Husbands, M. G., Sabb, A. L., Abou-Gharbia, M., Moyer, J. A. & Boast, C. A. (2000) The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist, J Pharmacol Exp Ther. 292, 584-96.
88. Abe, Y., Aoyagi, A., Hara, T., Abe, K., Yamazaki, R., Kumagae, Y., Naruto, S., Koyama, K., Marumoto, S., Tago, K., Toda, N., Takami, K., Yamada, N., Ori, M., Kogen, H. & Kaneko, T. (2003) Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease, J Pharmacol Sci. 93, 95-105.
89. Murai, T., Okuda, S., Tanaka, T. & Ohta, H. (2007) Characteristics of object location memory in mice: Behavioral and pharmacological studies, Physiol Behav. 90, 116-24.
90. Kang, S. Y., Lee, K. Y., Koo, K. A., Yoon, J. S., Lim, S. W., Kim, Y. C. & Sung, S. H. (2005) ESP-102, a standardized combined extract of Angelica gigas, Saururus chinensis and Schizandra chinensis, significantly improved scopolamine-induced memory impairment in mice, Life Sci. 76, 1691-705.
91. Mirza, N. R., Peters, D. & Sparks, R. G. (2003) Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists, CNS Drug Rev. 9, 159-86.
92. Perry, K. W., Nisenbaum, L. K., George, C. A., Shannon, H. E., Felder, C. C. & Bymaster, F. P. (2001) The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex, Biol Psychiatry. 49, 716- 25.
93. Byun, N. E., Grannan, M., Bubser, M., Barry, R. L., Thompson, A., Rosanelli, J., Gowrishankar, R., Kelm, N. D., Damon, S., Bridges, T. M., Melancon, B. J., Tarr, J. C., Brogan, J. T., Avison, M. J., Deutch, A. Y., Wess, J., Wood, M. R., Lindsley, C. W., Gore, J. C., Conn, P. J. & Jones, C. K. (2014) Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100, Neuropsychopharmacology. 39, 1578-93.
94. Poulin, S. P., Dautoff, R., Morris, J. C., Barrett, L. F. & Dickerson, B. C. (2011) Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity, Psychiatry Res. 194, 7-13.
95. Du, A. T., Schuff, N., Amend, D., Laakso, M. P., Hsu, Y. Y., Jagust, W. J., Yaffe, K., Kramer, J. H., Reed, B., Norman, D., Chui, H. C. & Weiner, M. W. (2001) Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease, J Neurol Neurosurg Psychiatry. 71, 441-7.
96. Mizuno, K., Wakai, M., Takeda, A. & Sobue, G. (2000) Medial temporal atrophy and memory impairment in early stage of Alzheimer's disease: an MRI volumetric and memory assessment study, J Neurol Sci. 173, 18-24.
97. Mosconi, L., Pupi, A., De Cristofaro, M. T., Fayyaz, M., Sorbi, S. & Herholz, K. (2004) Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease, J Nucl Med. 45, 382-92.
98. Nestor, P. J., Fryer, T. D., Smielewski, P. & Hodges, J. R. (2003) Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment, Ann Neurol. 54, 343-51.
99. Hazlett, E. A., Buchsbaum, M. S., Jeu, L. A., Nenadic, I., Fleischman, M. B., Shihabuddin, L., Haznedar, M. M. & Harvey, P. D. (2000) Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task, Schizophr Res. 43, 33-46.
100. Millan, M. J., Agid, Y., Brune, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., Dubois, B., Geyer, M. A., Goodwin, G. M., Gorwood, P., Jay, T. M., Joels, M., Mansuy, I. M., Meyer-Lindenberg, A., Murphy, D., Rolls, E., Saletu, B., Spedding, M., Sweeney, J., Whittington, M. & Young, L. J. (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy, Nat Rev Drug Discov. 11, 141-68.
101. Grannan, M. D., Mielnik, C. A., Moran, S. P., Gould, R. W., Ball, J., Lu, Z., Bubser, M., Ramsey, A. J., Abe, M., Cho, H. P., Nance, K. D., Blobaum, A. L., Niswender, C. M., Conn, P. J., Lindsley, C. W. & Jones, C. K. (2016) Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256, ACS Chem Neurosci. 7, 1706-1716.
102. Arnt, J. & Skarsfeldt, T. (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence, Neuropsychopharmacology. 18, 63-101.
103. Stanhope, K. J., Mirza, N. R., Bickerdike, M. J., Bright, J. L., Harrington, N. R., Hesselink, M. B., Kennett, G. A., Lightowler, S., Sheardown, M. J., Syed, R., Upton, R. L., Wadsworth, G., Weiss, S. M. & Wyatt, A. (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat, J Pharmacol Exp Ther. 299, 782- 92.
104. Shannon, H. E., Rasmussen, K., Bymaster, F. P., Hart, J. C., Peters, S. C., Swedberg, M. D., Jeppesen, L., Sheardown, M. J., Sauerberg, P. & Fink-Jensen, A. (2000) Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice, Schizophr Res. 42, 249-59.
105. Wikenheiser, A. M. & Schoenbaum, G. (2016) Over the river, through the woods: cognitive maps in the hippocampus and orbitofrontal cortex, Nat Rev Neurosci. 17, 513- 23.
106. Schobel, S. A., Kelly, M. A., Corcoran, C. M., Van Heertum, K., Seckinger, R., Goetz, R., Harkavy-Friedman, J. & Malaspina, D. (2009) Anterior hippocampal and orbitofrontal cortical structural brain abnormalities in association with cognitive deficits in schizophrenia, Schizophr Res. 114, 110-8.
107. Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., Suckling, J., Phillips, L. J., Yung, A. R., Bullmore, E. T., Brewer, W., Soulsby, B., Desmond, P. & McGuire, P. K. (2003) Neuroanatomical abnormalities before and after onset of psychosis: a cross- sectional and longitudinal MRI comparison, Lancet. 361, 281-8.
108. Crick, F. C. & Koch, C. (2005) What is the function of the claustrum?, Philos Trans R Soc Lond B Biol Sci. 360, 1271-9.
109. Morys, J., Bobinski, M., Wegiel, J., Wisniewski, H. M. & Narkiewicz, O. (1996) Alzheimer's disease severely affects areas of the claustrum connected with the entorhinal cortex, J Hirnforsch. 37, 173-80.
110. Girard-Joyal, O., Faragher, A., Bradley, K., Kane, L., Hrycyk, L. & Ismail, N. (2015) Age and sex differences in c-Fos expression and serum corticosterone concentration following LPS treatment, Neuroscience. 305, 293-301.
111. Procaccini, C., Maksimovic, M., Aitta-Aho, T., Korpi, E. R. & Linden, A. M. (2013) Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740, Neuroscience. 250, 189-200.
112. Stanisavljevic, A., Peric, I., Gass, P., Inta, D., Lang, U. E., Borgwardt, S. & Filipovic, D. (2019) Brain Sub/Region-Specific Effects of Olanzapine on c-Fos Expression of Chronically Socially Isolated Rats, Neuroscience. 396, 46-65.
113. Filipovic, D., Stanisavljevic, A., Jasnic, N., Bernardi, R. E., Inta, D., Peric, I. & Gass, P. (2018) Chronic Treatment with Fluoxetine or Clozapine of Socially Isolated Rats Prevents Subsector-Specific Reduction of Parvalbumin Immunoreactive Cells in the Hippocampus, Neuroscience. 371, 384-394.
114. Hitti, F. L. & Siegelbaum, S. A. (2014) The hippocampal CA2 region is essential for social memory, Nature. 508, 88-92.
115. Benes, F. M., Kwok, E. W., Vincent, S. L. & Todtenkopf, M. S. (1998) A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives, Biol Psychiatry. 44, 88-97.
116. Kim, Y., Venkataraju, K. U., Pradhan, K., Mende, C., Taranda, J., Turaga, S. C., Arganda-Carreras, I., Ng, L., Hawrylycz, M. J., Rockland, K. S., Seung, H. S. & Osten, P. (2015) Mapping social behavior-induced brain activation at cellular resolution in the mouse, Cell Rep. 10, 292-305.
117. Paxinos, G. & Franklin, K. B. J. (2001) The Mouse Brain in Stereotactic Coordinates (2 nd Edition), Academic Press, Inc: San Diego.
118. Maeda, S., Xu, J., FM, N. K., Clark, M. J., Zhao, J., Tsutsumi, N., Aoki, J., Sunahara, R. K., Inoue, A., Garcia, K. C. & Kobilka, B. K. (2020) Structure and selectivity engineering of the M1 muscarinic receptor toxin complex, Science. 369, 161- 167.
119. Maeda, S., Qu, Q., Robertson, M. J., Skiniotis, G. & Kobilka, B. K. (2019) Structures of the M1 and M2 muscarinic acetylcholine receptor/G-protein complexes, Science. 364, 552-557.
120. Bakker, G., Vingerhoets, C., Boucherie, D., Caan, M., Bloemen, O., Eersels, J., Booij, J. & van Amelsvoort, T. (2018) Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis, Neuroimage Clin. 18, 713-719.
121. Marino, M. J., Rouse, S. T., Levey, A. I., Potter, L. T. & Conn, P. J. (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D- aspartate (NMDA) receptor currents in hippocampal pyramidal cells, Proc Natl Acad Sci U S A. 95, 11465-70.
122. Davoren, J. E., Garnsey, M., Pettersen, B., Brodney, M. A., Edgerton, J. R., Fortin, J. P., Grimwood, S., Harris, A. R., Jenkinson, S., Kenakin, T., Lazzaro, J. T., Lee, C. W., Lotarski, S. M., Nottebaum, L., O'Neil, S. V., Popiolek, M., Ramsey, S., Steyn, S. J., Thorn, C. A., Zhang, L. & Webb, D. (2017) Design and Synthesis of gamma- and delta- Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity, J Med Chem. 60, 6649-6663.
123. Gautam, D., Heard, T. S., Cui, Y., Miller, G., Bloodworth, L. & Wess, J. (2004) Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice, Mol Pharmacol. 66, 260-7.
論文の公開元へ
